Drug facts
MoleculePregabalin (Lyrica)
Generics already compete: 25 makers on the market. 185 A-rated products from 25 makers substitute at the counter.
Lyrica was first approved by the FDA on 12/30/2004 under NDA 021446; the application holder is Upjohn US 2 LLC.
The latest NADAC for PREGABALIN 150 MG CAPSULE is $0.06 per unit (as of 10/28/2026).
Holder Upjohn US 2 LLCApplication NDA 021446Approved 12/30/2004
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
- Latest patent
- No Lyrica patent listed in the Orange Book Orange Book
- Later patents, other products
- Lyrica CR 05/02/2027 Orange Book
02Competition
- Generics
- 25 generic makers Orange Book
- First generic approved
- 07/19/2019 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Pregabalin profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $0.06 per unitPREGABALIN 150 MG CAPSULE, mid-priced of 8 strengths, as of 10/28/2026 CMS NADAC
- Latest recall
- 05/16/2024Class III, Pregabalin, Rising Pharma Holding, Inc. FDA enforcement
04Product
- Application holder
- Upjohn US 2 LLC Orange Book
- Application
- NDA 021446 Orange Book
- First approved
- 12/30/2004 Orange Book
- Dosage forms
- capsule; solution; tablet, extended release
- Routes
- oral
- Other brand names
- Lyrica CR
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.